Search

everythinglearnresearchcommunity

for

Search:↓

A 19-year-old male has been using topical finasteride and minoxidil for 8 months with no progress and is considering seeking a second opinion due to potential misdiagnosis. The discussion revolves around whether the hair loss is due to male pattern baldness, alopecia areata, or a vitamin deficiency.

User is experiencing severe hair loss despite using finasteride for 15 months, losing 500 hairs a day and 50% density since June. Minoxidil with needling was ineffective, and RU58841 is too expensive and hard to obtain.

The conversation discusses organizing group buys and tracking progress for Kx-826 Pyrilutamide, a hair loss treatment. Participants express optimism about upcoming results and concerns about self-reporting bias.

The user is considering using only minoxidil for hair loss due to financial constraints and is unsure if finasteride is necessary. They are also donating blood for money and cannot afford to stop.

A user's experience of gaining weight while taking Dutasteride, and suggestions on how to continue using it without the negative side effects, such as exercising and tracking calories or switching to Finasteride.

Kintor announced Phase 3 results for pyrilutamide, a hair loss treatment, in China. The conversation is focused on this announcement and its implications for hair loss treatment.

Hope Medicine received a $28M investment for HMI-115, a monoclonal antibody in phase II trials for treating androgenetic alopecia. Some users are skeptical about its effectiveness, while others find the investment and trial results encouraging.

The user is stressed about hair loss and is using a HIMS topical treatment containing finasteride, ketoconazole, minoxidil, and biotin, but is concerned about the oily appearance it causes. They are considering switching to Rogaine (minoxidil) due to budget constraints and side effect concerns with oral finasteride.

The user's consideration of taking finasteride as a short-term treatment, while awaiting advances in medical technology such as Pyrilutamide and GT20029; other users' experiences with Finasteride, including potential side effects.

Topical estradiol may help with hair loss but can have systemic effects, like reduced testosterone production. Using estrogen blockers can have negative side effects, such as joint pain and reduced sex drive.

The user is considering topical Saw Palmetto or Pumpkin Seed Oil due to sensitivity to finasteride and cost issues. They also use dermastamping for Minoxidil absorption and seek advice on timing to avoid systemic absorption.

The user is experiencing severe hair loss despite using treatments like DUT, oral minoxidil, ketoconazole, RU58841, and vitamins. They plan to buzz their hair due to the ongoing hair fall and its impact on their mental health and self-esteem.

Hair loss treatments discussed include 200mg Spiro, bicalutamide, and finasteride. Endocrinologist advises against bicalutamide and finasteride due to potency and risks.

The conversation discusses why CB-03-01, a potential hair loss treatment, isn't widely discussed despite evidence of its effectiveness and safety. Some users mention other treatments like melatonin, procianidin b2, and RU58841, debating their effectiveness and safety.

Finasteride is expensive in Germany, but cheaper alternatives are available in other countries like Turkey, Greece, and Russia. Users suggest traveling to these countries or seeking online prescriptions to save money.

A user is seeking alternatives to finasteride for hair loss during a planned break for family planning reasons. They inquire about pyrilutamide, cosmern, and other potential future treatments.

User asks about Pyrilutamide for hair loss and its cost. Questions include legitimacy of selleckchem, vehicle to use, and storage.

The conversation is about when GT20029, a hair loss treatment, might be available on the grey market, with users discussing the challenges of compounding it and speculating it might be available after phase 2 results, similar to pyri. Specific treatments mentioned are pyri, RU58841, and GT20029.

A man with thick, white hair is admired for his genetics, leading to discussions about hair loss and the preference for white hair over balding. Some speculate about the use of treatments like finasteride.

People with hair loss experience emotional struggles and body dysmorphia. Treatments like minoxidil, finasteride, and dutasteride are used, but results vary and can take time.

Hair loss can cause significant stress and anxiety, leading individuals to try various treatments like microneedling, hair transplants, and lifestyle changes. Some people find peace by accepting hair loss and focusing on other aspects of life, while others experience ongoing distress.

The conversation is about a user feeling hopeless due to hair loss despite using finasteride, dutasteride, and OM for over a year. Responses suggest therapy, self-improvement, and changing perspectives on appearance.

The conversation discusses the tension theory of baldness, suggesting that over-developed masseter muscles may harm hair follicles. Botox injections to relax these muscles reportedly led to an 18% increase in hair count in men with AGA.

Dutasteride users have mixed results in hair loss treatment, with some experiencing improvements and others worsening. Some report metabolic changes like weight gain or diabetes, while others have no significant side effects.

Scube3, a potential hair loss treatment, is unlikely to be released because it was given to a startup company, Amplifica, which may go bankrupt and fail to bring the treatment to market. Amplifica is prioritizing other treatments over Scube3, which could lead to financial loss and the end of Scube3's development.

Clascoterone solution is in Phase III trials for male androgenetic alopecia, with results expected in the second half of 2025. Commercialization is anticipated in about 2-3 years, but there are concerns about delays and market expectations.

Dutasteride once a week may be a cost-effective alternative to daily finasteride for reducing DHT levels, with potential benefits for those seeking a lighter approach to hair loss treatment. Some users combine dutasteride with finasteride, minoxidil, and dermarolling for improved results.

Pyrilutamide, a nonsteroidal antiandrogen drug under development for the potential treatment of androgenic alopecia. The conversation discusses its binding affinity to the androgen receptor and the timeline for possible availability after trials are completed in the United States and China.

The user is struggling with hair loss despite using topical minoxidil, finasteride, and oral dutasteride, and is seeking affordable alternatives to 2.5mg dutasteride. Suggestions include checking for scalp inflammation, considering oral minoxidil, using rosemary oil, and possibly trying saw palmetto, though results may vary.

A European individual planning to go to China is seeking information on how to participate in HMI-115 trials for Androgenetic Alopecia. They've tried contacting Mrs. Yang and Mr. Wang for assistance but haven't received a response.